Literature DB >> 22282007

[Multimodal laryngeal preservation: current data-based opinion].

A Dietz1, A Boehm, G Wichmann, D Niederwieser, S Dietzsch, M Fuchs.   

Abstract

This article presents the current data and discussion on multimodal laryngeal preservation strategies in advanced laryngeal/hypopharyngeal carcinoma. Principally a distinction is made between simultaneous and induction chemoradiation protocols. In terms of late toxicity and related functional limitations, induction protocols are far superior to simultaneous platinum-based chemoradiation. Currently, the individual response to the first cycle of (short) induction chemotherapy appears to be the most reliable clinical marker for making treatment decisions, and this is under clinical investigation. No standard multimodal therapeutic alternative to laryngectomy exists; therefore, at this time multimodal strategies should only be carried out within the framework of clinical trials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22282007     DOI: 10.1007/s00106-011-2416-7

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  33 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  The recording of morbidity related to radiotherapy.

Authors:  S Dische; M F Warburton; D Jones; E Lartigau
Journal:  Radiother Oncol       Date:  1989-10       Impact factor: 6.280

Review 3.  Functional outcomes following treatment for advanced laryngeal cancer. Part I--Voice preservation in advanced laryngeal cancer. Part II--Laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group.

Authors:  R E Hillman; M J Walsh; G T Wolf; S G Fisher; W K Hong
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1998-05

4.  EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

Authors:  Milena Sant; Claudia Allemani; Mariano Santaquilani; Arnold Knijn; Francesca Marchesi; Riccardo Capocaccia
Journal:  Eur J Cancer       Date:  2009-01-24       Impact factor: 9.162

5.  Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas--a possibility for organ preservation.

Authors:  Leo Pfreundner; Florian Hoppe; Jochen Willner; Verena Preisler; Klaus Bratengeier; Rudolf Hagen; Jan Helms; Michael Flentje
Journal:  Radiother Oncol       Date:  2003-08       Impact factor: 6.280

6.  Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.

Authors:  Johannes A Langendijk; Patricia Doornaert; Irma M Verdonck-de Leeuw; Charles R Leemans; Neil K Aaronson; Ben J Slotman
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

7.  [Chronic laryngeal edema as a late reaction to radiochemotherapy].

Authors:  A Dietz; V Rudat; J Nollert; M Helbig; B Vanselow; H Weidauer
Journal:  HNO       Date:  1998-08       Impact factor: 1.284

Review 8.  T3-4 squamous cell carcinoma of the larynx treated with radiation therapy alone.

Authors:  W M Mendenhall
Journal:  Semin Radiat Oncol       Date:  1998-10       Impact factor: 5.934

9.  Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial).

Authors:  Andreas Dietz; Volker Rudat; Jens Dreyhaupt; Maria Pritsch; Florian Hoppe; Rudolph Hagen; Leo Pfreundner; Ursula Schröder; Hans Eckel; Markus Hess; Michael Schröder; Petra Schneider; Bünzel Jens; Hans P Zenner; Jochen A Werner; Rita Engenhardt-Cabillic; Bernhard Vanselow; Peter Plinkert; Marcus Niewald; Thomas Kuhnt; Wilfried Budach; Michael Flentje
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-10-30       Impact factor: 2.503

10.  Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.

Authors:  Jean-Louis Lefebvre; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-01       Impact factor: 7.038

View more
  4 in total

1.  [Swallowing disorders after partial laryngectomy. Prevalence and predictors].

Authors:  A Meyer; A Dietz; D Wollbrück; J Oeken; H Danker; E F Meister; A Sandner; W Völkel; E Brähler; S Singer
Journal:  HNO       Date:  2012-10       Impact factor: 1.284

2.  hTERT gene knockdown enhances response to radio- and chemotherapy in head and neck cancer cell lines through a DNA damage pathway modification.

Authors:  Wojciech Barczak; Agnieszka Sobecka; Pawel Golusinski; Michal M Masternak; Blazej Rubis; Wiktoria M Suchorska; Wojciech Golusinski
Journal:  Sci Rep       Date:  2018-04-13       Impact factor: 4.379

3.  Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance.

Authors:  M M Gerlach; F Merz; G Wichmann; C Kubick; C Wittekind; F Lordick; A Dietz; I Bechmann
Journal:  Br J Cancer       Date:  2013-11-21       Impact factor: 7.640

Review 4.  The importance of stem cell engineering in head and neck oncology.

Authors:  Wojciech Barczak; Pawel Golusiński; Lukasz Luczewski; Wiktoria M Suchorska; Michal M Masternak; Wojciech Golusiński
Journal:  Biotechnol Lett       Date:  2016-06-24       Impact factor: 2.461

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.